Viridian Therapeutics to Present at Upcoming Investor Conferences
03 November 2021 - 9:05PM
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company
advancing new treatments for patients suffering from serious
diseases but underserved by today’s therapies, today announced that
Jonathan Violin, Ph.D., President and Chief Executive Officer, will
present a corporate overview at the Credit Suisse 30th Annual
Healthcare Conference and participate in fireside chats at the
Jefferies London Healthcare Conference and the Evercore ISI 4th
Annual HealthCONx Conference.
Credit Suisse
30th Annual Healthcare
Conference |
Format: |
Corporate Presentation |
Date: |
Monday, November 8, 2021 |
Time: |
8:50am EST |
|
|
Jefferies London Healthcare
Conference |
Format: |
Fireside Chat |
Date: |
Thursday, November 18, 2021 |
Time: |
8:00am GMT |
Webcast Link |
|
|
Evercore ISI 4th
Annual HealthCONx Conference |
Format: |
Fireside Chat |
Date: |
Wednesday, December 1, 2021 |
Time: |
10:55am EST |
Webcast Link |
About Viridian Therapeutics
Viridian Therapeutics is a biotechnology company
advancing new treatments for patients suffering from serious
diseases but underserved by today’s therapies. Viridian’s most
advanced program, VRDN-001, is a differentiated monoclonal antibody
targeting insulin-like growth factor-1 receptor (IGF-1R), a
clinically and commercially validated target for the treatment of
thyroid eye disease (TED). TED is a debilitating auto immune
disease that causes inflammation and fibrosis within the orbit of
the eye which can cause double vision, pain, and potential
blindness. Patients with severe disease often require multiple
remedial surgeries to the orbit, eye muscles and eyelids. Viridian
is based in Waltham, Massachusetts.
Viridian
Contacts:Investors:Dan FerryLifeSci
Advisors617-430-7576IR@viridiantherapeutics.com
Media:Darby PearsonVerge Scientific
Communications703-587-0831PR@viridiantherapeutics.com
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024